SGMT vs VKTX
SGMT: Sagimet Biosciences is a clinical-stage biotech developing oral FASN inhibitors to treat metabolic dysfunction-associated steatohepatitis (MASH) and other metabolic diseases. VKTX: Viking is developing VK2735, a novel dual GLP-1/GIP receptor agonist in Phase 3 trials for obesity and metabolic disorders, targeting a high-growth market currently dominated by single-agent GLP-1 therapies.
Side-by-side fundamentals
| Metric | SGMT | VKTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $7.05 | $37.31 | |
| Market cap as of 2026-07-23 | $431M | $4.3B | |
| PEG as of 2026-07-23 | n/a | -0.04 | |
| Net margin as of 2026-07-23 | -1393.8% | n/a | |
| Operating margin as of 2026-07-23 | -1537.0% | n/a | |
| ROE as of 2026-07-23 | -37.6% | -71.3% | SGMT higher |
| ROA as of 2026-07-23 | -35.5% | -65.3% | SGMT higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Beta as of 2026-07-23 | 3.45 | 0.65 | |
| 1-year return as of 2026-07-22 close | -26.6% | +16.2% | VKTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.